|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
FISH-determined HER-2/neu status is not associated with histologic type, tumor size, nodal status, lymph-vascular invasion, or patient age.
|
16297088 |
2005 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
The HER2/neu specificity of these gastric cancer-specific CTLs was demonstrated using HER2/neu-transfected cell lines and HER2/neu-expressing tumors, and with a set of HER2/neu-derived peptide epitopes.
|
9754653 |
1998 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
No objective tumor responses occurred in the HER2-negative cohort.
|
18283035 |
2008 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
We analyzed primary human breast cancers and found high cyclin D1 levels in a subset (approximately 25%) of ErbB-2-overexpressing tumors.
|
16413469 |
2006 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Human epidermal growth factor receptor 2 (HER2) is a tumor associated antigen over-expressed in 20-30% of cases of breast cancer.
|
29125981 |
2017 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
The optimization of maintenance therapy in patients with HER2-negative metastatic breast cancer must be based on disease profile (tumor subtype and endocrine-sensitive status), the prior use of bevacizumab-containing regimens, and the number of prognostic risk factors.
|
31054086 |
2019 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Triple negative breast cancer (TNBC), as defined by ER, PR and HER2 negative expression in tumor, has limited treatment options beyond conventional chemotherapy.
|
31700871 |
2019 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Recent research suggests that women who develop breast cancer between the ages of 30-34 may have specific tumour characteristics: Those with high grade, oestrogen receptor negative, human epidermal growth factor receptor 2 (HER-2) negative tumours have between a 10% and 27% chance of being a BRCA1 gene carrier.
|
15952973 |
2005 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Furthermore, HDAC1 over-expression was associated with positive estrogen receptor (ER) expression (OR, 3.30; 95% CI, 1.11-9.83; P = 0.03) and negative human epidermal growth factor receptor 2 (HER2) expression (OR, 1.79; 95% CI, 1.22-2.61; P = 0.003), but there were no significant differences between patients based on age, tumor size, lymph node metastasis, nuclear grade, or progesterone receptor (PR) expression.
|
29738697 |
2018 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Amplification was often high level with HER-2 copies ranging from 4 to 60 per tumor cell and was strongly related to protein overexpression.
|
20656317 |
2010 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Importantly, in vivo treatment experiments showed that one of the new immunotoxins could efficiently halt tumor growth at doses lower than 0.75 mg/kg, and it had a maximum tolerated dose (MTD) higher than 8.0 mg/kg, showing a substantially improved MTD and a broadened therapeutic window than the previously reported anti-HER2 immunotoxins.
|
31836485 |
2020 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
The expression of KLK6 is positively associated with tumor grade (P = 0.038) and is overexpressed in TNBC and HER2-positive tumors (P < 0.001).
|
29435805 |
2018 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
The ROC analysis identified a cut-off point of 26 mm of tumor size (area under the receiver operating characteristic [ROC] curve [AUC] 0.712, CI: 0.614-0.811) was useful for dividing patients with positive SLN (1-2 nodes) into non-SLN-positive and non-SLN-negative groups.For 1-2 positive SLNs of breast cancer, LVI, large invasive tumor size, and HER2 over-expression are independent factors affecting NSLN metastases.
|
30383658 |
2018 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
HER 2/neu gene amplification was observed in 4 (2.4%) of the 169 tumor specimens and in none of the normal tissues.
|
12767065 |
2003 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Overexpression of t-DARPP mRNA was detected in two-thirds of tumors with a correlation between ERBB2 and t-DARPP overexpression levels (r = 0.58, P = 0.003).
|
22745369 |
2012 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Furthermore, immunohistochemical staining revealed that several oncogenes and tumor suppressor genes, such as HER-2, C-myc, p53, and nm23, were expressed in H9, many of which were also shared by ovarian cancer. hESC vaccines can induce antitumor effects in two animal models and in ovarian cancer, indicating that the activity of the vaccine is universal, and, more importantly, it is safe.
|
23174760 |
2013 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Previous SPECT studies in xenografts have shown that the Affibody molecule (111)In-DOTA-Z(HER2)(:2395) can discriminate between high and low human epidermal growth factor receptor type 2 (HER2)-expressing tumors, indicating that radiolabeled Affibody molecules have potential for patient selection for HER2-targeted therapy.
|
22173842 |
2012 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Furthermore, low PPM1H expression may identify a subset of HER2-positive tumors that are harder to treat.
|
22586611 |
2011 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
erbB-2/Her-2 gene amplification and overexpression in parotid gland tumors.
|
8102855 |
1993 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Patients who underwent SLND alone were older (mean 60.6 years) with more comorbidities (Charlson-Deyo score > 2), smaller primary tumors (mean 2.1 cm), well-differentiated histology, hormone receptor-positive, HER2-negative tumors, without lymphovascular invasion (all P values < 0.01).
|
31025270 |
2019 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Within the training cohort, univariate and multivariate analyses suggested that estrogen receptor (ER) status, progesterone receptor (PR) status and tumor grade were significantly associated with HER2 status (P<0.01).
|
29212167 |
2017 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
HER2 overexpression was demonstrated in 19% (TAB 250), 23% (CB11), and 36% (A0485) of the tumors.
|
12065780 |
2002 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
HER2 protein expression was seen in 4 of 34 (12%) tumor samples that originated from 2 of 18 patients (11%).
|
16211448 |
2005 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
High expression of epidermal growth factor receptors [EGFR or human epidermal growth factor receptor 2 (HER2)] in IBC tumors has prompted trials of anti-EGFR/HER2 monoclonal antibodies to inhibit oncogenic signaling; however, de novo and acquired therapeutic resistance is common.
|
26821068 |
2016 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Upon expression of HER2, untransformed human mammary epithelial MCF-10A cells underwent neoplastic transformation, formed foci in culture and tumors in nude mouse xenografts.
|
20622894 |
2010 |